1. Scrip
  2. >>R&D

Ex-Sanofi Exec Stoeckli Primes Glenmark’s Cancer Therapy Ambitions

 
• By Anju Ghangurde

Glenmark’s president and chief scientific officer, Dr Kurt Stoeckli, believes that some big pharma companies may have missed the opportunity to embark on immunotherapy cancer treatment R&D “at the right time” and tells Scrip that there is room for the Indian firm to provide competitive assets in the space. Stoeckli, an ex-Sanofi senior executive, also outlines why the upside potential of Glenmark’s BEAT antibody technology platform is “remarkable”.

Dr Kurt Stoeckli, says that moving to Glenmark Pharmaceuticals Ltd. from Sanofi was all about a “perfect match.” While the former group vice president for the French multinational’s global biopharmaceuticals division may have been used to big pharma R&D budgets and scale, Stoeckli says that he was drawn to the Indian firm by its sheer potential – “people, project and science” - and what the company “could make” in the years to come.

“I just found that this is a perfect match, where I could bring complementarity and experience that I have gone...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from R&D

Multiple Factors Driving Japan’s Pioneering Angiosarcoma Pipeline

 
• By Lisa Takagi

Japan has emerged as a global leader in the development of new drugs for the rare cancer angiosarcoma, reflecting its rapidly ageing population and the limitations of current therapies.

Argenx Powers Ahead With Vyvgart’s Prefilled Syringe Launch

 
• By Andrew McConaghie

The Netherlands-headquartered company is enjoying huge success with Vyvgart in two autoimmune conditions, with a new prefilled syringe version reaching more patient groups.

Sanofi CFO Says Direct Sales To Patients ‘Certainly Worth Considering’

 
• By Kevin Grogan

François Roger believes fixing inefficiencies is more important than playing with pricing.

Vyne Seeks Partner For Repibresib After Phase IIb Vitiligo Fail

 
• By Alaric DeArment

The Phase IIb study failed its primary and a key secondary endpoint, but showed activity on another key secondary and an exploratory endpoint.

More from Scrip

Most Favored Nation Pricing: Trump Ups Pressure On Voluntary Action, Clarifies Demands

 
• By Sarah Karlin-Smith

The new 60-day deadline for striking a deal with the drug industry underscores the challenges the Administration may be having in developing non-voluntary policies to achieve MFN pricing in the US.

Multiple Factors Driving Japan’s Pioneering Angiosarcoma Pipeline

 
• By Lisa Takagi

Japan has emerged as a global leader in the development of new drugs for the rare cancer angiosarcoma, reflecting its rapidly ageing population and the limitations of current therapies.

Bristol’s Q2 Earnings Homerun Overshadowed By Clinical Trial Review Curveball

 
• By Mandy Jackson

Second quarter revenue and EPS beat consensus and BMS raised its 2025 revenue guidance, but after multiple recent Phase III failures, executives said the company is reviewing studies with near-term readouts.